Inclusion Criteria:

          -  Provide written informed consent prior to initiation of any study-specific procedures.

          -  Metastatic or advanced stage solid tumor.

          -  Known BRAF Class I, Class II, or Class III alteration as confirmed by previous genomic
             analysis of tumor tissue or ctDNA.

          -  Must have received prior standard therapy appropriate for the tumor type and stage of
             disease (including prior therapy with a BRAF inhibitor if FDA approved for the cancer
             type), OR unlikely to tolerate or derive clinically meaningful benefit from
             appropriate standard of care therapy.

          -  Measurable or evaluable disease by RECIST v1.1.

          -  ECOG performance status 0, 1, or 2.

          -  Adequate organ function, as measured by laboratory values (criteria listed in
             protocol).

          -  Able to swallow, retain, and absorb oral medications.

        Exclusion Criteria:

          -  Known active brain metastases from non-brain tumors.

          -  For tumor types and indications not approved by FDA, prior receipt of any BRAF-, MEK-,
             or MAPK-directed inhibitor therapy.

          -  GI tract disease causing an inability to take oral medication, malabsorption syndrome,
             requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.

          -  Seropositive for hepatitis B or hepatitis C.

          -  Women who are lactating or breastfeeding, or pregnant.

          -  In Dose Expansion, patients with BRAF Class I mutations are excluded.

        Complete inclusion and exclusion criteria are listed in the clinical study protocol.